Walt Disney Co vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Walt Disney Co trades at $108.05 (market cap $184.79B), while Nuvation Bio Inc. Class A Common Stock trades at $5 (market cap $1.74B). The key difference: Walt Disney Co is far larger — about 106.2× Nuvation Bio Inc. Class A Common Stock's market cap, and Walt Disney Co pays a 1.4% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Walt Disney Co for 199 Days and Nuvation Bio Inc. Class A Common Stock for 1 Days on average.
| DIS | NUVB | |
|---|---|---|
Market Cap | $184.79B | $1.74B |
Volume | 13,033,550 | 9,289,619 |
Sector | Media | Health |
52-Week High | $116.65 | $9.54 |
52-Week Low | $92.40 | $3.41 |
Typical Hold Time | 199 Days | 1 Days |
Enterprise Value | $225.65B | $1.33B |
Dividend Yield | 1.4% | — |
Signals from Pluang's Aura AI — not financial advice
Disney (DIS) trades at $107.08, up 2.21% today, with a bullish technical signal from moving averages and consistent earnings beats in recent quarters. Revenue grew to $94.43B in 2025, with net income surging to $12.40B, though free cash flow faces pressure from increased investments. The stock remains below the analyst consensus price target of $125.67, indicating potential upside.
The outlook is positive with strong fundamentals and analyst support, but risks include streaming competition and high capital expenditures. Investment opportunity lies in execution of the $60B parks pipeline and streaming margin expansion, balanced against macroeconomic sensitivity and execution risks.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
The Walt Disney Company is an entertainment company with operations in media networks, park experiences & consumer products, studio entertainment and Direct-to-Consumer networks and channels. The Company serves customers worldwide.
Read more on DIS →Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →